| Bioactivity | SARS-CoV-2-IN-25 (Compound CP026) is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC50 of 1.6 μM. SARS-CoV-2-IN-25 inhibits enveloped viruses and liposomes[1]. |
| Target | IC50: 1.5 μM (HIV-1), 1.6 μM (SARS-CoV-2 spike pseudoparticle transduction), 1.8 μM (SARS-CoV-2), 1.9 μM (MeV), 11.6 μM (IAV)EC50: 2.6 μM (liposome) |
| Invitro | SARS-CoV-2-IN-25 (Compound CP026) shows cytotoxicity with a CC50 of 117.9 μM against Caco2 cells[1].SARS-CoV-2-IN-25 inhibits SARS-CoV-2, IAV, MeV, HIV-1 with IC50s of 1.8, 11.6, 1.9 and 1.5 μM, respectively. SARS-CoV-2-IN-25 inhibits liposome with an EC50 of 2.6 μM[1]. |
| Name | SARS-CoV-2-IN-25 |
| Formula | C58H48O8P2 |
| Molar Mass | 934.94 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Weil T, et al. Advanced Molecular Tweezers with Lipid Anchors against SARS-CoV-2 and Other Respiratory Viruses. JACS Au, 2022. |